Market Overview

UPDATE: Credit Suisse Reiterates Neutral Rating, Raises PT on Medtronic

Share:
Related MDT
Medtronic Remains A Top Pick At UBS Following HeartWare Deal
Medtronic Reveals Beacon Heart Failure Management Service
Baxter Well Positioned in Fast-Growing Market for Kidney Dialysis Equipment (GuruFocus)

In a report published Wednesday, Credit Suisse Group reiterated its Neutral rating on Medtronic (NYSE: MDT), and slightly raised its price target from $46.00 to $47.00.

Credit Suisse noted, “We see the last 2 Qs as evidence of MDT's ability to drive an improving top-line through emerging markets execution, recovery in key developed markets & M&A. Given MDT's improving top-line and conservative guidance we believe the company is the best positioned among the large-cap cardio names for near-term share price upside (though we highlight added BMP fallout as a near-term risk). We're raising our price target to $47 from $46 on a lower assumed WACC.”

Medtronic closed on Tuesday at $42.66.

Latest Ratings for MDT

DateFirmActionFromTo
Jun 2016SunTrust Robinson HumphreyMaintainsBuy
Jun 2016Guggenheim SecuritiesInitiates Coverage onNeutral
Jun 2016Deutsche BankMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Credit Suisse GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!